Application of Cisplatin in Bletilla Hyacinthine Particle Chemotherapy Combined with 125Iodine Brachytherapy in Advanced Gastric Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 WANG Zhiquan ¹ , YANG Zhenlin ¹ , WANG Kaijun ¹ , WANG Jun ¹ , YAO Chunhe ¹ , ZHANG Qing ² , LI Qang ² , LI Hongxiao ²

1.Department of Hepatobiliary General Surgery, The Third Affiliated Hospital of Yan’an University Medical School, Xianyang 712000, Shaanxi Province, China;;
2.Shaanxi College of Traditional Chinese Medicine, Xianyang 712000, Shaanxi Province, China;

Corresponding author：

WANG Zhiquan , Email: wzq55102@163.com

Keywords：

Advanced gastric cancer; Bletilla hyacinthine; Cisplatin; 125Iodine; Brachytherapy; Chemotherapy

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the effect of cisplatin in bletilla hyacinthine particle chemotherapy combined with 125I brachytherapy on short-and long-term outcomes and the toxic and side effects in advanced gastric cancer. Methods One hundred seventy-six patients with stage Ⅱ or stage Ⅲ advanced gastric cancer underwent curative surgical resection were included in this study. They were randomly divided into brachytherapy and chemotherapy group (n=48), intraperitoneal chemotherapy group (n=32) and intravenous chemotherapy group (n=48), and other patients who abandoned radiotherapy and chemotherapy and signed informed consent form by themselves were considered as control group (n=48). The short-and long-term outcomes and the toxic and side effects were observed and the survival of all patients was analyzed by Kaplan-Meier method and Log-Rank test. Results For short-term outcomes, the total effective rate in 4 groups were 95.83%, 71.88%, 64.58% and 52.08% respectively, and the difference was significant (P lt;0.05). For long-term outcomes, the 3 -and 5-year mortality rate was 37.50% and 56.30%, and 5-year median survival time was (14±4.51) months (95%CI: 14.419-4.512) in brachytherapy and chemotherapy group patients. The 3- and 5-year mortality rate was 78.12%and 93.75%and 5year median survival time was (10.6±1.13) months (95%CI: 10.620-1.163) in intraperitoneal chemotherapy group patients. The 3-and 5-year mortality rate was 79.21%and 95.80%and 5-year median survival time was (11±3.10) months (95%CI: 11.130-3.162) in intravenous chemotherapy group patients. The 3-and 5-year mortality rate was 87.50%and 95.83% and 5-year median survival time was (9±2.30) months (95%CI: 10.024-1.180) in control group patients. Compared with the vein chemotherapy group, the short distance puts the chemotherapy group disgusting vomit, the marrow to suppress, the liver function harm, the kidney function harm formation rate to reduce obviously (P lt;0.05). Conclusion Cisplatin in bletilla hyacinthine particle chemotherapy combined with 125I brachytherapy can reduce the toxic and side effects of drugs and prolong survival time of patients with advanced gastric cancer.

Citation： WANG Zhiquan ,YANG Zhenlin,WANG Kaijun,WANG Jun,YAO Chunhe,ZHANG Qing,LI Qang,LI Hongxiao. Application of Cisplatin in Bletilla Hyacinthine Particle Chemotherapy Combined with 125Iodine Brachytherapy in Advanced Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2010, 17(1): 11-16. doi: Copy

1.	罗开元, 赵泉, 杨镛, 等. 125I粒子组织间植入对大肠癌的抑制作用及其机制 [J]. 中华试验外科杂志, 2006; 23(1): 7071.
2.	王娟, 隋爱霞, 贾漪涛, 等. 单纯放射性125I粒子植入治疗不能切除的Ⅳ期胃癌9例报告 [J]. 中国实用外科杂志, 2006; 26(7): 530532.
3.	吴在德, 吴肇汉. 外科学 [M]. 第6版. 北京: 人民卫生出版社, 2007: 462463.
4.	张小东主译. 肿瘤治疗学 [M]. 第1版. 北京: 人民卫生出版社, 2001: 494503.
5.	Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual [M]. 5th Ed. Philadelphia: LippincottRaven, 1997: 71.
6.	郭岳峰, 庞国明, 焦智民. 肿瘤病诊断全书 [M]. 第1版. 北京: 中国医药科技出版社, 2001: 655657.
7.	韩方海, 詹文华, 何裕隆, 等. 胃癌根治手术网膜囊及筋膜切除问题 [J]. 中国普外基础与临床杂志, 2007; 14(2): 230234.
8.	何启明, 伍晓汀. 碘125籽源在胃癌术中植入治疗中的应用 [J]. 华西医学, 2009; 24(2): 509510.
9.	朱正纲. 胃癌外科治疗相关问题的基本认识 [J]. 中国普外基础与临床杂志, 2008; 15(1): 13.
10.	赵吉生, 郑泽霖, 郑扶民. 胃网膜动脉插管区域性化疗治疗晚期胃癌 [J]. 中国普外基础与临床杂志, 1998; 5(1): 4344.
11.	何运胜, 姜淮芜. 进展期胃癌多模式治疗的研究进展 [J]. 中国普外基础与临床杂志, 2008; 15(1): 3135.
12.	黄斌, 李昂, 张波, 等. 纳米炭吸附5FU淋巴靶向化疗对胃癌组织及转移淋巴结bcl2、bax及caspase3表达的影响 [J]. 中国普外基础与临床杂志, 2009; 16(1): 1822.
13.	王舒宝, 王俊. 胃癌复发与转移的有关问题及综合治疗 [J]. 中国普外基础与临床杂志, 2006; 13(1): 911.
14.	Douglass HO Jr. Gastric cancer: overview of current therapies [J]. Semin Oncol, 1985; 12(3 Suppl 4): 5762.
15.	韩朝阳, 曹道俊, 李富梅, 等. 进展期胃癌术前氟尿嘧啶腹腔和静脉化疗药代动力学的比较研究 [J]. 中国普通外科杂志, 2001; 10(3): 262263.
16.	解乃昌, 林进令. 进展期胃癌临床治疗的现状 [J]. 中国普外基础与临床杂志, 2006; 13(1): 5255.
17.	刘福坤, 姚学权. 胃癌的新辅助化疗 [J]. 中国普外基础与临床杂志, 2006; 13(1): 1720.
18.	詹文华. 胃癌手术前化疗的研究现状 [J]. 中华胃肠外科杂志, 2005; 8(5): 471473.
19.	Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy [J]. Br J Surg, 1989; 76(10): 10821090.
20.	徐霞, 刘萃红, 许世华, 等. 顺铂可降解淀粉微球家兔动脉栓塞药动学研究 [J]. 海峡药学, 2001; 13(1): 2325.
21.	黄斌, 陈志新. 胃癌淋巴靶向化疗的研究进展 [J].中国普外基础与临床杂志, 2006; 13(5): 617620.
22.	葛勤, 刘同华, 黄林清. 中药白芨作为血管栓塞剂及药物载体的研究概况 [J]. 中国药房, 2003; 14 (5): 305307.
23.	梁寒, 王仆, 王晓娜, 等. 活性碳吸附丝裂霉素C腹腔化疗预防进展期胃癌术后复发 [J]. 中华外科杂志, 2003; 41(4): 274277.
24.	何运胜, 张华, 姜淮芜. 进展期胃癌术前辅助性放化疗的研究现状 [J]. 中国现代普通外科进展, 2007; 10(3): 243246.
25.	Popescu CC, Wise J, Sowards K, et al. Dosimetric characterstics of the Pharma Seed model BT125I source [J]. Med Phys, 2000; 27(9): 21742181.
26.	Portilla AG, Sugarbaker PH, Chang D. Secondlook surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features [J]. World J Surg, 1999; 23(1): 2329.
27.	岳麓, 桂律, 陈红红, 等. 125I植入对小鼠移植性实体瘤抑制效果 [J]. 中华放射医学与防护杂志, 2003; 23(5): 314316.

1. 罗开元, 赵泉, 杨镛, 等. 125I粒子组织间植入对大肠癌的抑制作用及其机制 [J]. 中华试验外科杂志, 2006; 23(1): 7071.
2. 王娟, 隋爱霞, 贾漪涛, 等. 单纯放射性125I粒子植入治疗不能切除的Ⅳ期胃癌9例报告 [J]. 中国实用外科杂志, 2006; 26(7): 530532.
3. 吴在德, 吴肇汉. 外科学 [M]. 第6版. 北京: 人民卫生出版社, 2007: 462463.
4. 张小东主译. 肿瘤治疗学 [M]. 第1版. 北京: 人民卫生出版社, 2001: 494503.
5. Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual [M]. 5th Ed. Philadelphia: LippincottRaven, 1997: 71.
6. 郭岳峰, 庞国明, 焦智民. 肿瘤病诊断全书 [M]. 第1版. 北京: 中国医药科技出版社, 2001: 655657.
7. 韩方海, 詹文华, 何裕隆, 等. 胃癌根治手术网膜囊及筋膜切除问题 [J]. 中国普外基础与临床杂志, 2007; 14(2): 230234.
8. 何启明, 伍晓汀. 碘125籽源在胃癌术中植入治疗中的应用 [J]. 华西医学, 2009; 24(2): 509510.
9. 朱正纲. 胃癌外科治疗相关问题的基本认识 [J]. 中国普外基础与临床杂志, 2008; 15(1): 13.
10. 赵吉生, 郑泽霖, 郑扶民. 胃网膜动脉插管区域性化疗治疗晚期胃癌 [J]. 中国普外基础与临床杂志, 1998; 5(1): 4344.
11. 何运胜, 姜淮芜. 进展期胃癌多模式治疗的研究进展 [J]. 中国普外基础与临床杂志, 2008; 15(1): 3135.
12. 黄斌, 李昂, 张波, 等. 纳米炭吸附5FU淋巴靶向化疗对胃癌组织及转移淋巴结bcl2、bax及caspase3表达的影响 [J]. 中国普外基础与临床杂志, 2009; 16(1): 1822.
13. 王舒宝, 王俊. 胃癌复发与转移的有关问题及综合治疗 [J]. 中国普外基础与临床杂志, 2006; 13(1): 911.
14. Douglass HO Jr. Gastric cancer: overview of current therapies [J]. Semin Oncol, 1985; 12(3 Suppl 4): 5762.
15. 韩朝阳, 曹道俊, 李富梅, 等. 进展期胃癌术前氟尿嘧啶腹腔和静脉化疗药代动力学的比较研究 [J]. 中国普通外科杂志, 2001; 10(3): 262263.
16. 解乃昌, 林进令. 进展期胃癌临床治疗的现状 [J]. 中国普外基础与临床杂志, 2006; 13(1): 5255.
17. 刘福坤, 姚学权. 胃癌的新辅助化疗 [J]. 中国普外基础与临床杂志, 2006; 13(1): 1720.
18. 詹文华. 胃癌手术前化疗的研究现状 [J]. 中华胃肠外科杂志, 2005; 8(5): 471473.
19. Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy [J]. Br J Surg, 1989; 76(10): 10821090.
20. 徐霞, 刘萃红, 许世华, 等. 顺铂可降解淀粉微球家兔动脉栓塞药动学研究 [J]. 海峡药学, 2001; 13(1): 2325.
21. 黄斌, 陈志新. 胃癌淋巴靶向化疗的研究进展 [J].中国普外基础与临床杂志, 2006; 13(5): 617620.
22. 葛勤, 刘同华, 黄林清. 中药白芨作为血管栓塞剂及药物载体的研究概况 [J]. 中国药房, 2003; 14 (5): 305307.
23. 梁寒, 王仆, 王晓娜, 等. 活性碳吸附丝裂霉素C腹腔化疗预防进展期胃癌术后复发 [J]. 中华外科杂志, 2003; 41(4): 274277.
24. 何运胜, 张华, 姜淮芜. 进展期胃癌术前辅助性放化疗的研究现状 [J]. 中国现代普通外科进展, 2007; 10(3): 243246.
25. Popescu CC, Wise J, Sowards K, et al. Dosimetric characterstics of the Pharma Seed model BT125I source [J]. Med Phys, 2000; 27(9): 21742181.
26. Portilla AG, Sugarbaker PH, Chang D. Secondlook surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features [J]. World J Surg, 1999; 23(1): 2329.
27. 岳麓, 桂律, 陈红红, 等. 125I植入对小鼠移植性实体瘤抑制效果 [J]. 中华放射医学与防护杂志, 2003; 23(5): 314316.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Application of Cisplatin in Bletilla Hyacinthine Particle Chemotherapy Combined with 125Iodine Brachytherapy in Advanced Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content